Alpha Tau Medical (DRTS) is in focus as it nears key clinical trial updates. Enrollment for its high-stakes IMPACT trial (pancreatic cancer) and ReSTART study (skin cancer) is expected to finish by Q1 2026. Retail sentiment is high, with traders watching for data that could validate its targeted Alpha DaRT radiation tech.